Eli Lilly (LLY) shares dropped after its latest earnings report and disappointing results for an oral GLP-1 pill. Lee Brown joins Sam Vadas to discuss the phase 3 trial and says "the markets missing the big picture here" believing "tolerability" is the key focal point. He points to the differences in Novo Nordisk (NVO) and LLY weight-loss drug offerings. Lee dives into Mounjaro's cardio-protective results as well, saying it might be "overlooked" in today's report.